Announcements and Notices - [Overseas Regulatory Announcement - Business Update]

HUTCHMED (China) Limited develops, manufactures, and sells pharmaceutical products. The Company offers drugs for oncology and autoimmune diseases treatment. HUTCHMED (China) markets its products worldwide.

Voluntary Announcement - Hutchmed Announces Launch By Takeda Of Fruzaqla (Fruquintinib) In Japan

Announcements and Notices - [List of Directors and their Role and Function]

List Of Directors And Their Roles And Functions

Announcements and Notices - [Change in Directors or of Important Executive Functions or Responsibilities]

Hutchmed Announces Appointment Of Independent Non-Executive Director And Member Of Board Committee

Voluntary Announcement - Hutchmed Highlights Clinical Data To Be Presented At The 2024 Ash Annual Meeting And The 2024 Esmo Asia Congress

Announcements and Notices - [Overseas Regulatory Announcement - Other]

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Hutchmed China Ltd (13 HK)

Voluntary Announcement - Hutchmed Announces Launch By Takeda Of Fruzaqla (Fruquintinib) In Japan

List Of Directors And Their Roles And Functions

Hutchmed Announces Appointment Of Independent Non-Executive Director And Member Of Board Committee

Voluntary Announcement - Hutchmed Highlights Clinical Data To Be Presented At The 2024 Ash Annual Meeting And The 2024 Esmo Asia Congress

Total Voting Rights

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)